-
公开(公告)号：US09155872B2
公开(公告)日：2015-10-13
申请号：US13486540
申请日：2012-06-01
CPC分类号： A61M31/00 , A61B17/42 , A61B17/43 , A61M2210/1408 , A61M2210/1425
摘要： A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes.
摘要翻译： 药物输送装置被设计成通过与输卵管直接接触直接将药剂递送至卵巢。 该装置由三个主要部件组成：管状插入器，圆柱形腔和柱塞。 该装置是一种单一使用的涂抹器，其设计成类似于棉塞的形状，以便于其插入穿过阴道并进入子宫。 通过使用超声波将器械定位在子宫中央。 将腔室插入管状插入器中。 调整插入到管状插入器中的腔室的长度控制从管状插入器中的孔释放的管道的量。 超声波用于确保每个管道在每个输卵管入口处的正确放置。 柱塞被插入到腔室中，并且柱塞的调节控制释放到管中的药剂的量。
-
公开(公告)号：US20130144163A1
公开(公告)日：2013-06-06
申请号：US13486540
申请日：2012-06-01
IPC分类号： A61M31/00
CPC分类号： A61M31/00 , A61B17/42 , A61B17/43 , A61M2210/1408 , A61M2210/1425
摘要： A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes.
摘要翻译： 药物输送装置被设计成通过与输卵管直接接触直接将药剂递送至卵巢。 该装置由三个主要部件组成：管状插入器，圆柱形腔和柱塞。 该装置是一种单一使用的涂抹器，其设计成类似于棉塞的形状，以便于其插入通过阴道并进入子宫。 通过使用超声波将器械定位在子宫中央。 将腔室插入管状插入器中。 调整插入到管状插入器中的腔室的长度控制从管状插入器中的孔释放的管道的量。 超声波用于确保每个管道在每个输卵管入口处的正确放置。 柱塞被插入到腔室中，并且柱塞的调节控制释放到管中的药剂的量。
-
公开(公告)号：US20160001051A1
公开(公告)日：2016-01-07
申请号：US14851483
申请日：2015-09-11
CPC分类号： A61M31/00 , A61B17/42 , A61B17/43 , A61M2210/1408 , A61M2210/1425
摘要： A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes.
摘要翻译： 药物输送装置被设计成通过与输卵管直接接触直接将药剂递送至卵巢。 该装置由三个主要部件组成：管状插入器，圆柱形腔和柱塞。 该装置是一种单一使用的涂抹器，其设计成类似于棉塞的形状，以便于其插入穿过阴道并进入子宫。 通过使用超声波将器械定位在子宫中央。 将腔室插入管状插入器中。 调整插入到管状插入器中的腔室的长度控制从管状插入器中的孔释放的管道的量。 超声波用于确保每个管道在每个输卵管入口处的正确放置。 柱塞被插入到腔室中，并且柱塞的调节控制释放到管中的药剂的量。
-
4.发明授权Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells 有权使用睾丸内Sertoli细胞将纳米颗粒靶向药物递送至肺公开(公告)号：US09161901B2
公开(公告)日：2015-10-20
申请号：US12918265
申请日：2009-02-23
申请人： Arun Kumar , Shyam S. Mohapatra , Don F. Cameron
发明人： Arun Kumar , Shyam S. Mohapatra , Don F. Cameron
IPC分类号： A61K35/48 , A61K9/00 , A61B5/00 , A61K9/50 , A61K9/51 , A61K31/12 , A61K47/36 , A61K47/46 , A61K47/48 , A61K49/00 , B82Y5/00
CPC分类号： A61K31/12 , A61B5/0071 , A61B5/4848 , A61K9/0019 , A61K9/5068 , A61K9/5161 , A61K47/36 , A61K47/46 , A61K47/61 , A61K47/6901 , A61K47/6939 , A61K49/0043 , A61K49/0093 , A61K49/0097 , B82Y5/00 , C12N5/0683
摘要： A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.
摘要翻译： 提供了通过静脉内注射负载有与感兴趣的化合物结合的多个壳聚糖纳米颗粒的Sertoli细胞将感兴趣的化合物递送到受试者的肺的方法。 睾丸衍生的大鼠支持细胞预先装载有或不含药物姜黄素的壳聚糖纳米颗粒，用荧光细胞标记物预先标记，然后静脉内注射到对照或哮喘小鼠模型宿主中。 完整的预加载，预先标记的Sertoli细胞在注射后15分钟存在于肺中，似乎被夹带在肺泡囊周围的肺前毛细血管血管床中，但注射后1小时不存在，尽管Sertoli细胞标记和细胞 碎片是。 在注射后15分钟，大部分注射的纳米粒子负载（70％）和姜黄色素负荷（80％）分别存在于肺中，并且在注射后1小时分别保持在70％和80％。
-
公开(公告)号：US07892553B2
公开(公告)日：2011-02-22
申请号：US11799367
申请日：2007-04-30
申请人： Shyam S. Mohapatra , Arun Kumar
发明人： Shyam S. Mohapatra , Arun Kumar
IPC分类号： A61K39/395 , B82B3/00
CPC分类号： A61K9/5146 , A61K9/5161 , Y10S977/739 , Y10S977/746 , Y10S977/747 , Y10S977/90
摘要： The present invention pertains to nanoparticles, comprising a metal and/or polymer core, with 7-alpha hydroxylase, or an enzymatically active fragment thereof, nicotinamide adenine dinucleotide (NADH) and antibodies, or antibody fragments, specific for low density lipoprotein (LDL), attached to the core. The invention also concerns methods for reducing LDL cholesterol in a human or animal subject by administering nanoparticles of the invention. In a preferred embodiment, both circulating LDL and plasma cholesterol levels are reduced in the subject.
摘要翻译： 本发明涉及包含具有7-α羟化酶或其酶活性片段，特异于低密度脂蛋白（LDL）的烟酰胺腺嘌呤二核苷酸（NADH）和抗体或抗体片段的金属和/或聚合物核心的纳米颗粒， ，附在核心。 本发明还涉及通过施用本发明的纳米颗粒来降低人或动物受试者中的LDL胆固醇的方法。 在优选的实施方案中，受试者中循环LDL和血浆胆固醇水平都降低。
-
6.发明授权公开(公告)号：US07371738B2
公开(公告)日：2008-05-13
申请号：US11279956
申请日：2006-04-17
IPC分类号： A01N43/04
CPC分类号： H01F1/0054 , A61K9/1075 , A61K9/143 , A61K9/5123 , A61K9/5161 , A61K47/61 , A61K47/6921 , A61K47/6923 , A61K47/6929 , A61K48/0075 , B82Y5/00 , Y10S977/788 , Y10S977/797 , Y10S977/798 , Y10S977/801 , Y10S977/93
摘要： The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described. The present invention will be useful in methods of transdermal drug delivery using hyaluronic acid nanoparticles, among other uses.
摘要翻译： 本发明涉及用于施用活性分子，肽，DNA和/或其它亲水或疏水分子的透明质酸和透明质酸混合纳米颗粒体系的开发，透明质酸和透明质酸混合纳米颗粒体系的组合物，以及 其开发和使用程序。 这些纳米颗粒由盐形式的透明质酸，优选聚合物的钠盐或与磁性Fe颗粒杂交组成。 纳米颗粒基本上来自天然聚合物，生物相容性和生物可降解性。 纳米颗粒允许其转运的活性分子的受控释放及其朝向靶组织的取向。 本发明教导了一种制备直径小于180nm的透明质酸颗粒的方法，其包含活性成分，而与其亲水性或疏水性无关。 描述了制备颗粒的步骤。 除了其它用途之外，本发明可用于使用透明质酸纳米粒子的透皮药物递送方法。
-
7.发明申请公开(公告)号：US20080214494A1
公开(公告)日：2008-09-04
申请号：US12105884
申请日：2008-04-18
申请人： Shyam S. Mohapatra , Arun Kumar
发明人： Shyam S. Mohapatra , Arun Kumar
IPC分类号： A61K31/722 , C07H3/00 , C07H21/00 , C07K2/00
CPC分类号： A61K9/0092 , A61K48/0041 , A61K49/00 , C08B37/003 , C12N15/88 , Y10S977/742 , Y10S977/75 , Y10S977/753
摘要： Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.
摘要翻译： 与纳米壳聚糖复合的功能化单壁碳纳米管（SWCNT）用于递送生物物质和诊断应用。 与壳聚糖NG042复合的fSWCNT用于递送编码DNA的EGFP报道蛋白和肽。 结果表明，显示的CNT-壳聚糖杂化纳米颗粒在体内显示比单独的壳聚糖显着更高的转染效率。 此外，测试功能化纳米管的肽转移到HEK293细胞中。 结果表明，杂交纳米颗粒有效转移肽。 一起，这些结果表明混合SWCNT-壳聚糖颗粒增加DNA和肽转移到细胞中。
-
8.发明申请Nano-Based Device for Detection of Disease Biomarkers and Other Target Molecules 审中-公开用于检测疾病生物标志物和其他目标分子的纳米基装置公开(公告)号：US20080100279A1
公开(公告)日：2008-05-01
申请号：US11747125
申请日：2007-05-10
申请人： Shyam S. Mohapatra , Arun Kumar
发明人： Shyam S. Mohapatra , Arun Kumar
IPC分类号： G01N33/48
CPC分类号： G01N33/743 , C12Q1/005 , C12Q1/32 , G01N33/5438
摘要： The present invention pertains to a nano-based sensing device (a sensor) comprising a nano-scale working electrode that can be used for the ultra-sensitive detection of blood analytes, disease biomarkers, and other target molecules. The present invention also pertains to a method for detecting analytes using the sensor as the sensor element of a microfluidic device.
摘要翻译： 本发明涉及一种纳米级感测装置（传感器），其包括可用于血液分析物，疾病生物标志物和其他目标分子的超敏感检测的纳米级工作电极。 本发明还涉及使用该传感器作为微流体装置的传感器元件检测分析物的方法。
-
公开(公告)号：US10272053B2
公开(公告)日：2019-04-30
申请号：US14879649
申请日：2015-10-09
申请人： Arun Kumar , Shyam S. Mohapatra , Don F. Cameron
发明人： Arun Kumar , Shyam S. Mohapatra , Don F. Cameron
IPC分类号： A61K31/12 , A61B5/00 , A61K9/00 , A61K9/50 , A61K9/51 , A61K47/36 , A61K47/46 , A61K49/00 , B82Y5/00 , C12N5/071 , A61K47/61 , A61K47/69
摘要： A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.
-
10.发明申请公开(公告)号：US20140023588A1
公开(公告)日：2014-01-23
申请号：US13965527
申请日：2013-08-13
申请人： Shyam S. Mohapatra , Arun Kumar
发明人： Shyam S. Mohapatra , Arun Kumar
CPC分类号： A61K9/0092 , A61K48/0041 , A61K49/00 , C08B37/003 , C12N15/88 , Y10S977/742 , Y10S977/75 , Y10S977/753
摘要： Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.
摘要翻译： 与纳米壳聚糖复合的功能化单壁碳纳米管（SWCNT）用于递送生物物质和诊断应用。 与壳聚糖NG042复合的fSWCNT用于递送编码DNA的EGFP报道蛋白和肽。 结果表明，显示的CNT-壳聚糖杂化纳米颗粒在体内显示比单独的壳聚糖显着更高的转染效率。 此外，测试功能化纳米管的肽转移到HEK293细胞中。 结果表明，杂交纳米颗粒有效转移肽。 一起，这些结果表明混合SWCNT-壳聚糖颗粒增加DNA和肽转移到细胞中。
-
-
-
-
-
-
-
-
-
搜索结果
69 条记录 (耗时 0.025 秒)
